Golimumab
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Golimumab: From Inflammatory Arthritis and Spondyloarthritis to Rheumatoid Vasculitis
One-Sentence Summary
Golimumab is an anti-TNF-alpha antibody, originally used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis. The TxGNN model predicts it may be effective for rheumatoid vasculitis. The supporting evidence is weak: 1 clinical trial and 6 publications were found, and none directly tests golimumab in rheumatoid vasculitis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, inflammatory bowel disease (from the knowledge graph; Singapore licence records contain no indication text) |
| Predicted New Indication | Rheumatoid vasculitis |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Golimumab is a fully human monoclonal antibody that neutralizes TNF-alpha. This cytokine drives joint inflammation in rheumatoid arthritis and also plays a role in vascular inflammation. Detailed mechanism-of-action data were not available in the data compiled for this report, but the antibody's mode of action is described in the published reviews.
Rheumatoid vasculitis is a serious extra-articular complication of rheumatoid arthritis, mostly seen in long-standing, seropositive disease. Golimumab's efficacy in rheumatoid arthritis, together with the shared TNF-driven inflammation, gives the prediction a plausible mechanistic basis.
However, the retrieved evidence is only indirect. It contains no study of golimumab in rheumatoid vasculitis. One case report describes Takayasu arteritis arising during anti-TNF therapy, which raises a concern about paradoxical vasculitis. The mechanistic link is therefore plausible but unproven.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Recruiting | 80 | Compares how long rheumatology patients hold immunosuppressants before elective shoulder replacement, measuring flares, pain, function and wound complications. It does not test golimumab for vasculitis, so relevance is minimal. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31491879 | 2019 | Network meta-analysis (36 RCTs) | Int J Mol Sci | Original and biosimilar TNF inhibitors, including golimumab, reduce joint destruction in rheumatoid arthritis to a similar degree. |
| 23557513 | 2013 | Review | BMC Med | Update on biologic therapy for autoimmune diseases, covering benefits, cost and adverse events. |
| 27591827 | 2017 | Review | Semin Arthritis Rheum | Frequency and causes of end-stage renal disease in rheumatoid arthritis, and how to treat the arthritis in that setting. |
| 23252659 | 2013 | Case report | Ocul Immunol Inflamm | Behçet disease-associated uveitis treated successfully with golimumab. |
| 22999907 | 2013 | Case report | Joint Bone Spine | Two cases of Takayasu arteritis that appeared during anti-TNF therapy, a paradoxical-vasculitis signal. |
| 29075910 | 2018 | Case report | Rheumatol Int | Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient on golimumab. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN14734P | Simponi® I.V. Concentrate for Solution for Infusion 12.5mg/1 ml | Infusion, solution concentrate |
| SIN16118P | Simponi Solution for Injection in Pre-filled Pen 45mg/0.45ml | Injection, solution |
| SIN14735P | Simponi Solution for Injection in Pre-filled Syringe 100 mg/1.0 ml (Smartject Injector) | Injection, solution |
| SIN14105P | Simponi Solution for Injection in Pre-filled Syringe 50 mg/0.5 ml (Smartject Injector) | Injection, solution |
All four licences are valid single-ingredient products. The records contain no approved-indication text.
Safety Considerations
- Drug Interactions (100 interactions recorded; the main ones from the 20 reviewed are listed):
- Major: systemic and topical corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, triamcinolone, budesonide); deferiprone; radiopharmaceuticals and radioimmunotherapies (iobenguane I-131, ibritumomab tiuxetan, tositumomab).
- Moderate: metronidazole, tinidazole, rosuvastatin, simvastatin.
- Minor: zinc salts (sulfate, acetate, gluconate).
- Risk signals from the literature:
- TNF blockade increases infection risk, including tuberculosis and herpes zoster.
- Takayasu arteritis has appeared during anti-TNF therapy.
- Golimumab is expected to be harmful in IL-12/IFN-gamma pathway deficiencies, because it further weakens antimycobacterial immunity.
Please refer to the package insert for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The score is high (99.73%), and a TNF-based mechanism is plausible. But no trial or study directly tests golimumab in rheumatoid vasculitis. The only trial is unrelated, and the literature consists of general reviews and case reports. One case report even shows vasculitis emerging under anti-TNF therapy. Evidence stays at L4, which does not support moving forward.
To proceed, the following is needed:
- Direct clinical evidence, such as case series, cohort data or trials of anti-TNF therapy in rheumatoid vasculitis, with specific attention to paradoxical vasculitis
- The package insert warnings and contraindications from the Singapore regulator (HSA) for a proper safety review
- Detailed mechanism-of-action data from DrugBank
- A safety plan covering TB screening, vaccination status, infection monitoring and steroid co-medication
- Consideration of the other predicted indications for golimumab, which have stronger evidence but mostly overlap with its approved uses (inflammatory spondylopathy and polyarticular juvenile arthritis)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.